Heparin-induced thrombocytopenia and thrombosis: Better understanding of pathogenesis and improving diagnosis and treatment

肝素诱导的血小板减少症和血栓形成：更好地了解发病机制并改进诊断和治疗

• 批准号: nhmrc : 1028803
• 负责人: Prof Beng Chong
• 金额: $ 43.55万
• 依托单位: The University of New South Wales
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2012
• 资助国家: 澳大利亚
• 起止时间: 2012-01-01 至 2014-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/heparin-induced-thrombocytopenia-diagnosis-treatment/110662
• 关键词: Heparin; induced; thrombocytopenia; thrombosis; Better

Heparin, a widely used drug, can cause an adverse effect which results in a fall of the platelet count and the development of serious thrombosis. This drug complication is mediated by an immune mechanism. This proposal aims to provide a better understanding of the disease mechanism. It also aims to develop a new test that will improve the diagnosis, and to produce a novel drug that will effectively suppress the immune reaction and improve the treatment.

肝素是一种广泛使用的药物，可引起血小板计数下降和严重血栓形成的不良反应。这种药物并发症是由免疫机制介导的。这一建议旨在更好地了解疾病机制。它还旨在开发一种新的测试方法，以提高诊断水平，并生产一种能够有效抑制免疫反应并改善治疗的新药。